

# ASTRO DAILY NEWS



## SCHEDULE-AT-A-GLANCE

Sunday, September 29

**7:55 a.m. - 9:15 a.m.**

**PRO 08** - Implementation of a Prostate SBRT Program in the Community Setting

📍 Room 146

**8:00 a.m. - 9:00 a.m.**

**Early Career Committee Meeting** (open to all)

📍 East Salon C

**8:00 a.m. - 9:00 a.m.**

**SS 01** - Breast Cancer 1: Clinical Trials

📍 Room 202

**8:00 a.m. - 9:00 a.m.**

**EDU 03** - Navigating Medical Insurance Delays and Denials: Insights from Patients, ASTRO and the Press

📍 Room 209

**8:00 a.m. - 9:00 a.m.**

**International 01** - Implementing Innovations for Radiotherapy Delivery in Low- and Middle-Income Countries: Challenges and Opportunities

📍 Room 144

**8:00 a.m. - 9:00 a.m.**

**EDU 01** - Mechanisms of Non-Apoptotic Cell Death and Implications for Radiation and Immunotherapy

📍 Room 152

**8:00 a.m. - 9:00 a.m.**

**EDU 02** - Knowledge is Power: A Decade of RO-ILS Experience

📍 Room 140

**8:00 a.m. - 9:00 a.m.**

**SS 02** - GYN 1: Developmental Therapies and Quality Assurance in Early Phase Gynecologic Clinical Trials

📍 Room 204

**8:00 a.m. - 9:00 a.m.**

**SS 03** - Phys 1: Dosimetry and Treatment Planning

📍 Room 147

*Continued on page 3*

## Welcome to Washington, DC

BY HOWARD SANDLER, MD, MS, FASTRO

I'm so pleased to welcome you to Washington, DC! This meeting's planning has been underway for well over a year, and I am excited to show you what we have in store for you over the next four days!



The theme of the meeting is Targeting Provider Wellness for Exceptional Patient Care. I hope this theme, which is woven throughout many sessions, inspires conversations about how a healthy balance between work, family and personal wellness can lead to enhanced outcomes for patients.

Today begins our 66th annual gathering of the Society and, while I haven't attended 66 meetings, I have been to quite a few. In fact, I recall attending my first ASTRO meeting at the Fountainbleu Hotel in Miami, when our Annual Meeting was small enough to be held in a large hotel convention facility. Since then, we have grown quite a bit. ASTRO's fully grown-up Annual Meeting is a rich source of activities, and I hope you spend the next few days connecting with friends and colleagues, attending as many educational sessions as possible, learning from the more than 79 oral abstract sessions and 1,700 posters, and reviewing the exciting technologies on display in the robust Exhibit Hall!

As ASTRO's President, I'm personally excited about today's Presidential Symposium (see page 4 for the schedule). I dedicated this year's session to GU Cancers, my area of clinical focus. We've broken the Symposium into three parts focusing on prostate, renal and bladder cancers to highlight new approaches for these three sites that are ready for clinical implementation now. Later this afternoon, attend the Clinical Trials session where you will hear presentations from eight trials showcasing promising advances in treatments.

Starting tomorrow, we welcome our first of two keynote talks, both of which focus on our meeting

theme. Bryan Sexton, PhD, director of the Duke Center for Healthcare Safety and Quality, will present on the science of bite-sized well-being interventions to counteract burnout. Before Dr. Sexton takes the stage, ASTRO's incoming CEO, Vivek Kavadi, MD, MBA, FASTRO, will share his strategic vision as he prepares for his new role starting in November.

Monday afternoon I hope you will join me for my Presidential Address, where I will speak to the potential relationships between provider well-being and clinical outcomes. Directly following, hear from four potentially practice changing studies in the Plenary Session.

Tuesday morning we will hear from our second keynote, Danielle Ofri, MD, PhD, a practicing physician and author at NYU Grossman School of Medicine and Bellevue Hospital. Dr. Ofri will focus on the importance of humanism in medicine, the impact of technology on physician-patient relationships, and strategies for preventing burnout. I hope many of you will stay in the main session room to collectively applaud and celebrate this year's awardees during the Awards Ceremony. The 2024 Class of Fellows will be inducted, and we will award our Mentorship Award recipients, the 2024 Gold Medalists and our Honorary Member.

All of this, plus many, many sessions, posters, puppies — yes, puppies! — games, speed mentoring, networking opportunities, receptions and so much more! I look forward to seeing you all throughout the halls of the convention center and hope you enjoy ASTRO's 66th Annual Meeting in Washington, DC! 🇺🇸

Inside  
This  
Issue

### PRESIDENTIAL SYMPOSIUM

See today's lineup and schedule of presenters for the three sessions of the Presidential Symposium.

Page 4

### EXCITING NEWS FROM APEx

APEx unveils new accreditation for radiopharmaceutical therapy and implements significant updates since the launch of the program.

Page 7

### ABSTRACT AWARD WINNERS

Meet the 2024 Annual Meeting Abstract Award Winners.

Page 8

### SOCIAL CHAMPIONS

Meet the #ASTRO24 Social Champions. Follow them and #ASTRO24 for live meeting coverage on X (Twitter).

Page 11

[Read more](#) >>

# Join us for an Industry-Expert Theater presentation

## PSMA-Targeted Radioligand Therapy in mCRPC: A Precision Approach

A discussion of the clinical data and safety profile of a prescription treatment for patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy.



**Tom Boike, MD, MMM, FASTRO**  
Medical Director  
Novartis

Dr Boike is an employee of Novartis.



### Theater Assignment:

Exhibit Hall C - Theater 2



### Presentation Date and Time:

Tuesday, October 1, 2024  
12:00 – 1:00 PM

**Scan to vote on the patient case you want to hear presented!**



#### Indication

PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.

#### IMPORTANT SAFETY INFORMATION

##### Risk From Radiation Exposure

PLUVICTO contributes to a patient's long-term cumulative radiation exposure, which is associated with an increased risk for cancer.

Minimize radiation exposure to patients, medical personnel, and household contacts during and after treatment with PLUVICTO consistent with institutional practices, patient treatment procedures, Nuclear Regulatory Commission patient-release guidance, and instructions to the patient for follow-up radiation protection.

Ensure patients increase oral fluid intake and advise them to void as often as possible to reduce bladder radiation.

To minimize radiation exposure to others, advise patients to limit close contact (less than 3 feet) with household contacts for 2 days or with children and pregnant women for 7 days, to refrain from sexual activity for 7 days, and to sleep in a separate bedroom from household contacts for 3 days, from children for 7 days, or from pregnant women for 15 days.

##### Myelosuppression

PLUVICTO can cause severe and life-threatening myelosuppression. In the VISION study, grade 3 or 4 decreased hemoglobin (15%), decreased platelets (9%), decreased leukocytes (7%), and decreased neutrophils (4.5%) occurred in patients treated with PLUVICTO. Grade  $\geq 3$  pancytopenia occurred in 1.1% of patients (including 2 fatal events). Two deaths (0.4%) due to intracranial hemorrhage and subdural hematoma in association with thrombocytopenia were observed. One death due to sepsis and concurrent neutropenia was observed.

Perform complete blood counts before and during treatment with PLUVICTO. Withhold, reduce dose, or permanently discontinue PLUVICTO and clinically treat patients based on severity of myelosuppression.

#### Renal Toxicity

PLUVICTO can cause severe renal toxicity. In the VISION study, grade 3 or 4 acute kidney injury (3%) and increased creatinine (0.9%) occurred in patients treated with PLUVICTO.

Advise patients to remain well hydrated and to urinate frequently before and after administration of PLUVICTO. Perform kidney function laboratory tests, including serum creatinine and calculated creatinine clearance (CrCl), before and during treatment. Withhold, reduce dose, or permanently discontinue PLUVICTO based on severity of renal toxicity.

#### Embryo-Fetal Toxicity

The safety and efficacy of PLUVICTO have not been established in females. Based on its mechanism of action, PLUVICTO can cause fetal harm. No animal studies using lutetium Lu 177 vipivotide tetraxetan have been conducted to evaluate its effect on female reproduction and embryo-fetal development; however, all radiopharmaceuticals, including PLUVICTO, have the potential to cause fetal harm. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with PLUVICTO and for 14 weeks after the last dose.

#### Infertility

The recommended cumulative dose of 44.4 GBq of PLUVICTO results in a radiation-absorbed dose to the testes within the range where PLUVICTO may cause temporary or permanent infertility.

#### Adverse Reactions

The most common adverse reactions ( $\geq 20\%$ ) occurring at a higher incidence in patients who received PLUVICTO plus best standard of care (BSoC) were fatigue, dry mouth, nausea, anemia, decreased appetite, and constipation. Clinically relevant adverse reactions in  $< 5\%$  of patients included dry eye, vertigo, and pancytopenia (including bicytopenia).

#### Laboratory Abnormalities

The most common laboratory abnormalities that worsened from baseline in  $\geq 30\%$  of patients who received PLUVICTO plus BSoC were decreased lymphocytes, decreased hemoglobin, decreased leukocytes, decreased platelets, decreased calcium, and decreased sodium.

Please see full Prescribing Information at [www.pluvicto.com](http://www.pluvicto.com)





# SCHEDULE AT A GLANCE

Sunday, September 29

**8:00 a.m. - 9:00 a.m.**

**QP 01** - GU 4: GU Quick Pitch  
📍 Room 207 B

**9:15 a.m. - 9:30 a.m.**

**Welcome 01** - Welcome to ASTRO's Annual Meeting  
📍 Ballroom A/B/C

**9:30 a.m. - 10:20 a.m.**

**Presidential Symposium:** Innovations in Genitourinary Cancers: Session I - Renaissance of Radiotherapy for RCC  
📍 Ballroom A/B/C

**10:00 a.m. - 5:00 p.m.**

**Exhibit Hall Open**  
📍 Halls A/B/C, Lower Level

**10:20 a.m. - 11:10 a.m.**

**Presidential Symposium:** Innovations in Genitourinary Cancers: Session II - Bladder Preservation - A Modern Choice for Patients  
📍 Ballroom A/B/C

**11:00 a.m. - 2:30 p.m.**

**2024 Aspiring Scientists and Physicians Program for Underrepresented Populations**  
📍 Room 143

**11:10 a.m. - 12:00 p.m.**

**Presidential Symposium:** Innovations in Genitourinary Cancers: Session III - Radiotherapy for Prostate Cancer: Innovations You Can Implement Today  
📍 Ballroom A/B/C

**12:15 p.m. - 12:45 p.m.**

**How to Become a FASTRO**  
📍 East Salon C

**1:00 p.m. - 2:15 p.m.**

**PRO 09** - Head and Neck Cancer - Prevention and Management of Radiation Therapy Toxicity  
📍 Room 146

**1:00 p.m. - 2:30 p.m.**

**Clinical Trials Session**  
📍 Ballroom A/B/C

**1:15 p.m. - 1:45 p.m.**

**Why Now is the Right Time to Become an Authorized User for RPT**  
📍 East Salon C

**2:00 p.m. - 2:30 p.m.**

**Explore RT Answers on Epic MyChart Care Companion**  
📍 East Salon C

**2:15 p.m. - 3:30 p.m.**

**PRO 10** - Introduction to Theranostics for the Community Radiation Oncologist  
📍 Room 146

**2:30 p.m. - 3:00 p.m.**

**One-on-One: Hands on MyChart Care Companion**  
📍 East Salon C

**2:30 p.m. - 4:15 p.m.**

**Workshop 03** - No Longer "Taboo": An Interactive Workshop for Providers Navigating Compassionate Conversations with Sexual and Gender Minority (SGM) Patients  
📍 Room 145

**2:30 p.m. - 4:30 p.m.**

**EDU 04** - Fine ART: Ever Evolving Online Adaptive Radiotherapy Technologies and Clinical Innovations  
📍 Room 147

**2:30 p.m. - 4:30 p.m.**

**EDU 05** - SITC Advances in Cancer Immunotherapy (ACI) for Radiation Oncologists  
📍 Room 209

**2:30 p.m. - 5:30 p.m.**

**International 02** - Innovations in Radiation Oncology in Latin America  
📍 Room 144

**2:45 p.m. - 3:45 p.m.**

**SS 06** - Bio 1: Cancer Biology, DNA Repair, DNA Damage Response  
📍 Room 152

**2:45 p.m. - 3:45 p.m.**

**QP 02** - Nursing 1: Nursing/Supportive Care Quick Pitch  
📍 Room 158

**2:45 p.m. - 4:00 p.m.**

**EDU 07** - Challenges and Solutions for Capturing Better Normal Tissue Dose/Volume/Outcome Data to Facilitate its Analyses  
📍 Room 140

**2:45 p.m. - 4:00 p.m.**

**EDU 06** - A Case-Based Interactive Discussion of the ASTRO Clinical Practice Guideline for HPV-Positive Oropharyngeal Squamous Cell Carcinoma  
📍 Room 202

**2:45 p.m. - 4:00 p.m.**

**SS 07** - GYN 3: Quest for Prognostic and Predictive Biomarkers in Gynecological Malignancies  
📍 Room 207 B

**2:45 p.m. - 4:00 p.m.**

**SS 05** - Palliative 1: Faster, Less Toxic, and More Effective: A Holy Trinity in Palliative Radiotherapy  
📍 Room 151

**2:45 p.m. - 4:00 p.m.**

**SS 04** - PRO/QoL/Survivorship 1: New Frontiers in Patient Reported Outcomes and Survivorship  
📍 Room 204

**2:45 p.m. - 4:15 p.m.**

**Workshop 04** - Grant Writing Workshop  
📍 Room 150

**2:45 p.m. - 4:15 p.m.**

**PQA 01** - Lung Cancer/Thoracic Malignancies and Diversity, Equity and Inclusion in Healthcare Poster Q&A  
📍 Hall C

**3:00 p.m. - 4:00 p.m.**

**Speed Mentoring I**  
📍 East Salon C  
See page 5 for topics/mentors.

**4:00 p.m. - 4:30 p.m.**

**ASTRO 2024 Social Media Meetup**  
📍 ASTRO Sign in the Grand Lobby

**4:45 p.m. - 5:45 p.m.**

**EDU 36** - What I Wish I Knew in the Early Career Period  
📍 Room 158

**4:45 p.m. - 6:00 p.m.**

**EDU 10** - Moving Beyond Auditory Speech: Improving Equity for Patients and Providers with Diverse Communication Needs  
📍 Room 140

**4:45 p.m. - 6:00 p.m.**

**International 03** - Reirradiation in Clinical Practice: Navigating Current Evidence and Practical Solutions  
📍 Room 143

**4:45 p.m. - 6:00 p.m.**

**EDU 11** - Pitfalls, Perils and Pearls: Identifying and Managing Gynecologic Treatment Toxicity  
📍 Room 209

**4:45 p.m. - 6:00 p.m.**

**EDU 13** - At the Cutting Edge: The Increasing Role of Salvage Radiotherapy in Relapsed/Refractory Lymphomas  
📍 Room 204

**4:45 p.m. - 6:00 p.m.**

**EDU 12** - Relevant or Relegated? Radiotherapy for Stage III NSCLC in the Neoadjuvant Era  
📍 Room 146

**4:45 p.m. - 6:00 p.m.**

**EDU 09** - Update on ASTRO's Partial Breast Irradiation Guidelines: Case-Based Interactive Discussion  
📍 Room 202

**4:45 p.m. - 6:00 p.m.**

**EDU 08** - Blood-Based Cancer Screening Tests: An Overview of Developing Technologies, Early Prospective Clinical Trial Results and Opportunities for Radiation Oncologists  
📍 Room 151

**4:45 p.m. - 6:00 p.m.**

**SS 09** - CNS 2: CNS Metastases and Normal Tissue Toxicity  
📍 Room 147

**4:45 p.m. - 6:00 p.m.**

**SS 10** - DHI 1: Exploring the Future of AI, Radiomics, and Deep Learning in Radiation Oncology Research  
📍 Room 207 B

**4:45 p.m. - 6:00 p.m.**

**SS 08** - H&N 3: Addressing High-Risk Challenges Head On: Mitigating Toxicity and Reducing Recurrences  
📍 Room 152

**4:45 p.m. - 6:00 p.m.**

**PQA 02** - Physics Poster Q&A  
📍 Hall C

**5:00 p.m. - 6:00 p.m.**

**ARRO Mentoring and Networking Reception**  
📍 Room 206

**6:00 p.m. - 7:00 p.m.**

**Informal Early Career Reception** (Cash Bar)  
📍 East Salon C

**6:00 p.m. - 8:00 p.m.**

**LGBTQIA+ And Allies Meetup**  
📍 Marriott Marquis, Shaw Room

## ASTRO Daily News 2024

Issue Number 1 | Sunday Edition

Publisher:

Laura I. Thevenot

Editorial Director:

Anna M. Arnone

Managing Editor:

Diane Kean

Design/Production:

Jaimie Hernandez

Contributing Editors:

Lisa Braverman

Alex Carrigan

Jennifer Jang

# STREET TALK

## What is one thing you want attendees to know about your session?



"The **GU quick pitch session** promises to highlight new and exciting research for treatment of men with prostate cancer, ranging from advances in the intact, locally advanced setting, all the way to the metastatic castrate-resistant setting, as well as in the post-operative space. The results of these trials will pave the way for new indications for RT in prostate cancer, as well as introduce novel technologies and ideas that may improve clinical outcomes and quality of life for our patients."

– Sophia C. Kamran, MD



"This year I will be participating in **EDU 32**, an ASTRO/JASTRO Joint Session on Advances in Liver Cancer Radiation Therapy on Monday afternoon. In this exciting session, we will review the vast experience in the use of radiation therapy (photons, protons and even carbon) to treat hepatocellular carcinoma (HCC) with a lens through North America and Japan, reviewing radiation therapy for cure in early stage, for improved local control, progression free survival and overall survival in intermediate and advanced stages, for reducing and eliminating tumor vascular invasion and for palliation of hepatic pain. Together, we should have better ability to advocate for increased and appropriate use of radiation therapy as a standard clinical treatment for HCC and also for inclusion in future trials and international guidelines."

– Laura Dawson, MD, FRCPC, FASTRO



"In **Scientific Session 23**, we studied our department's transition from virtual to in-person peer review by monitoring case discussion, change recommendations, and by prospectively surveying participants on their engagement, perceptions and preferences about the peer review format. We identified

substantial decreases in peer review discussion rates and plan change recommendations in the cases reviewed virtually."

– Ryan Hughes, MD



## Presidential Symposium

Sunday, September 29  
9:30 a.m. - 12:00 p.m.

**ORGANIZED AND INTRODUCED** by ASTRO President Howard Sandler, MD, MS, FASTRO, the Presidential Symposium will highlight New Innovations in Genitourinary Cancers. The symposium sessions will review advances in multidisciplinary approaches for kidney, bladder and prostate cancers.

"Radiation therapy plays an important role in the management of GU cancers, and it is timely to provide an update of new approaches that are ready for immediate clinical implementation, including microboost for prostate cancers, SBRT for primary renal cell cancers, and updated strategies for trimodality bladder preservation for muscle invasive urothelial bladder cancers," said Dr. Sandler. The sessions will serve as a catalyst for applying these strategies in clinical practice.

### Symposium Introduction

9:30 a.m. - 9:35 a.m.

**Speakers:** ASTRO President Howard Sandler, MD, MS, FASTRO, Cedars-Sinai Medical Center

### Session I: Renaissance of Radiotherapy for RCC

9:35 a.m. - 10:20 a.m.

**Moderator:** Shankar Siva, PhD, MBBS, Peter MacCallum Cancer Centre

#### Speakers:

- ISABR for RCC – Is It Ready For Primetime?: Shankar Siva, PhD, MBBS, Peter MacCallum Cancer Centre
- Strategies and Evidence for SABR in RCC: Chad Tang, MD, The University of Texas MD Anderson Cancer Center
- Medical Oncologist Perspective: Rana McKay, MD, University of California San Diego

### Session II: Bladder Preservation – A Modern Choice for Patients

10:20 a.m. - 11:10 a.m.

**Moderator:** Leslie Ballas, MD, FASTRO, Cedars-Sinai Medical Center

#### Speakers:

- Updates in TMT: The Future Is Now: Leslie Ballas, MD, FASTRO, Cedars-Sinai Medical Center
- Practical Use of Bladder Radiation Therapy: Ananya Choudhury, PhD, University of Manchester
- Medical Oncologist Perspective: Gopakumar Iyer, MD, Memorial Sloan Kettering Cancer Center

### Session III: Radiotherapy for Prostate Cancer: Innovations You Can Implement Today

11:10 a.m. - 12:00 p.m.

**Moderator:** Ronald Chen, MD, MPH, FASTRO, University of Kansas Medical Center


#### Topics and Speakers:

- Microboost Review: Brandon Mahal, MD, University of Miami/Sylvester Comprehensive Cancer Center
- Re-irradiation for Local Recurrence: Ronald Chen, MD, MPH, FASTRO, University of Kansas Medical Center
- Oligometastatic SBRT: Phuoc Tran, MD, PhD, University of Maryland Baltimore, School of Medicine

## Stop by the ASTRO Resource Center 📍 East Salon A/B, Street Level

Open daily starting at 7:00 a.m.

ASTRO representatives will be available to answer questions about the Annual Meeting, ASTRO membership, continuing education, MOC requirements, session and meeting evaluations and provide information on any of ASTRO's products and services. They can also offer assistance with the Annual Meeting Portal. Badge ribbons will be available for pickup for 25-year members, APEx participants, RO-ILS participants and *ASTRONews* Editorial Board members.







# Lively Discussions Held at 2024 Fall Board of Directors Meeting

Current and incoming ASTRO Board of Directors

**EACH YEAR, THE ASTRO BOARD OF DIRECTORS** meets in conjunction with the ASTRO Annual Meeting. On Friday morning, September 27, ASTRO CEO Laura Thevenot presented the results of the member survey. The Board keyed in on two specific areas: a declining level of satisfaction by early career members and low engagement in ASTRO by private and community practice. A robust conversation ensued about how to get members in these categories involved and more satisfied with ASTRO.

The Early Career Committee (ECC) is already making strides toward reaching out to their colleagues for feedback about how to add value to ASTRO membership. At this year's meeting, the ECC will hold an open Committee meeting to encourage dialogue. An Early Career member survey will be sent out later this Fall.

Board of Directors Chair Jeff Michalski, MD, MBA, FASTRO, called for a task force to better integrate community practice physicians into ASTRO committees as a pathway to leadership in the Society. The task force will be chaired by incoming President Sameer Keole, MD, FASTRO.

The Board agenda was packed with many operational and business topics. An update on the ASTRO Annual Meeting was provided, followed by an informative discussion about the metrics considered when selecting sites for future Annual Meetings, the ASTRO budget policy and updates on ASTRO's involvement in the delivery of radiopharmaceutical therapies. An invited guest presented on a recent

Supreme Court decision that ruled that courts need not defer to federal agencies on certain matters, and how that ruling may impact future policy and advocacy.









On Saturday morning, September 28, the Board previewed a new patient awareness campaign, "Radiation Therapy in Focus." The campaign is intended to raise awareness of radiation therapy's value and help people with cancer know their treatment options. ASTRO's Public Relations and Digital Communications departments reported about social media engagement and Society-sponsored patient materials. Election results, award announcements and journal article posts fare exceptionally well on social media. Spanish language patient materials are very popular and the Board discussed translating existing materials into additional languages.

The Radiation Therapy for Rectal Cancer Guideline update was approved for publication in *PRO*. Additionally, on Saturday morning there were presentations from the Association of Residents in Radiation Oncology (ARRO), the Association of Directors of Radiation Oncology Programs (ADROP), the American Board of Radiology (ABR) and the Radiation Oncology Institute (ROI). The Editors-in-Chief of ASTRO's three journals reported on the current state of these scientific publications; the journals are each receiving submissions near record-breaking 2020 levels.

Immediately following the meeting, the Board hosted a luncheon for ASTRO's international society counterparts. 

## ASTRO SPEED MENTORING SCHEDULE

SUNDAY, SEPTEMBER 29 · 3:00 p.m. – 4:00 p.m. |  Early Career and Mentoring Lounge, East Salon C

<p><b>TABLE 1</b> A Career in Radiation Oncology: Things to Consider</p>  <p>Malcolm Mattes, MD</p>	<p><b>TABLE 2</b> Contract Negotiation</p>  <p>Nicholas Zaorsky, MD, MS</p>	<p><b>TABLE 3</b> Navigating and Maximizing the Mentor-Mentee Relationship</p>  <p>Vinita Takiar, MD, PhD</p>	<p><b>TABLE 4</b> Fitting a Family into Your Career</p>  <p>Avinash Chaurasia, MD</p>
<p><b>TABLE 5</b> How to Ace the Interview</p>  <p>Theodore Lawrence, MD, PhD, FASTRO</p>	<p><b>TABLE 6</b> How to Get Involved with Journal Editorial Boards</p>  <p>Rachel Jimenez, MD</p>	<p><b>TABLE 7</b> How to Expand Access to Care in Rural Practices</p>  <p>Anna Paulsson, MD</p>	<p><b>TABLE 8</b> Making the Leap from Trainee to Attending Personally and Professionally</p>  <p>Austin Sim, MD, JD</p>

### 2024 CORPORATE AMBASSADORS

ASTRO proudly recognizes the ongoing commitment of our Corporate Ambassadors for their outstanding year-round leadership and promotional sponsorship of radiation oncology.







# Best™ medical international

A TEAMBEST GLOBAL COMPANY

## Best™ Integrated Brachytherapy Solutions

You don't go to a shoe store and cut your feet to fit the shoe they have in stock ... then why compromise when it comes to improving the clinical outcome for your patients?



Best™ Universal Chair/Table

Best™ HDR Remote Afterloader



BestMick Applicator



BestMick 10/15/20/25 Cartridges



Best™ Kobold Tandem & Ring Applicator


Best™ Kobold Fletcher Tandem & Ovoid Applicator

Best™ Kobold Henschke Tandem & Ovoid Applicator

Best™ Compact Sonalis™ Ultrasound Imaging System



Best™ X-ray Marker Cables




mobileMOSFET Wireless Dosimetry System



Portable Dosimetry System

Best™ Templates




Best™ Stepper/Stabilizer




Best™ Treatment Planning System



Best™ Esophageal Brachytherapy Applicator




Best™ Breast Double-Balloon Brachytherapy Applicator



Best™ Localization Needles with I-125 Seeds

Best™ Fiducial Markers




Best™ Iodine-125 Seed



Best™ Palladium-103 Seed



Best™ Flexi Needles



15G Flexi Needle

16G Flexi Needle

17G Flexi Needle

15G Flexi Needle with SS Sleeve (Click Fit)

Flexi Needle with Female Hub



Huestis CVO-2000 Warming Oven for Thermoplastics



We ship your order within 24 hours, 7 days a week, anywhere in the world!  
Standard or customized marker configuration made to your exact specifications, sterile or non-sterile!

Best Medical International, 7643 Fullerton Road, Springfield, VA 22153

tel: 703 451 2378 800 336 4970 [www.besttotalsolutions.com](http://www.besttotalsolutions.com) [www.teambest.com](http://www.teambest.com)

\*Certain products shown are not available for sale currently. TeamBest Global Companies ©2024





## Weekend programming supports the future of the field


**THE 2024 ANNUAL MEETING WELCOMED** more than 400 medical students as both in person and virtual attendees. ASTRO provides programming dedicated to this cohort to introduce them to the field of radiation oncology and supply information about what it is like to be a radiation oncologist. Last year, the Association of Residents in Radiation Oncology (ARRO) saw an opportunity for expanded programming that would specifically target this demographic and hosted the inaugural ASTRO-ARRO Medical Student Workshop. ARRO held the second annual workshop on Saturday where students heard more about opportunities within the field, navigating interview season, how to thrive during the intern year and transitioning into radiation oncology residency.

In 2019, the Aspiring Scientists and Physicians Program (ASPP) began and robust programming continues. Attendance is complimentary. Last year, complimentary virtual attendance was added in addition to the program's in-person offerings. Attendees are provided with networking opportunities with leaders in the field and are encouraged to engage in cutting-edge radiation oncology technology demonstrations.

"The Aspiring Scientists and Physicians Program is vital because it introduces underrepresented students to the field of radiation oncology at a pivotal stage in their education. By providing early exposure, mentorship, and access to a network of professionals, the program reveals radiation oncology as the hidden gem it often is. Our goal is

to expose students to the diverse and fulfilling career opportunities within the field.

We are intentional about including students at different stages of their educational journey. Through this program, we showcase the beautiful diversity already present in radiation oncology and emphasize that these students are welcome, needed, and belong here. Programs like this are essential for inspiring the next generation of diverse physicians who will shape the future of cancer care and address healthcare disparities," said ASPP champion, Phylicia Gawu, DO, MS.

Fueling multifaceted engagement with radiation oncology, including driving interest in the field for years to come, remains a top priority of the Annual Meeting. 



## Exciting News: APEX Unveils NEW Accreditation for Radiopharmaceutical Therapy

**THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY (ASTRO)** is excited to introduce a new radiopharmaceutical therapy (RPT) option within APEX - Accreditation Program for Excellence. This new offering is designed to recognize your practice for staying at the cutting edge of radiation oncology while maintaining alignment with national standards. As treatments and technologies evolve, ASTRO remains committed to keeping APEX adaptable and in sync with the changing landscape. The introduction of RPT accreditation reflects this commitment, offering practices an opportunity to enhance their services and gain recognition among the community, field and pharmaceutical companies for their expertise.

### What's new?

2024 marks a major milestone for APEX, with the most significant updates since the program's inception in 2014. ASTRO has revised standards, enhanced practice guidance, and launched a new platform that makes APEX more accessible, transparent and user-friendly. A key component of this update is the addition of an RPT-specific assessment, which underscores ASTRO's dedication to supporting the use and continued growth of radiopharmaceuticals.

APEX continues to be the fastest growing radiation oncology accreditation program in the United States, and the inclusion of RPT supports APEX remaining comprehensive and forward focused.

### Why RPT accreditation matters

Accreditation for RPT is essential for practices looking to demonstrate their commitment to the highest standards of safety, quality and effectiveness in this rapidly growing field. As the use of RPT expands, so does the need for standardized practices that support patient safety and consistent treatment outcomes. By undergoing RPT accreditation, practices not only show their dedication to excellence in patient care and rigorous staff training but also maintain compliance with national standards from ASTRO, AAPM and others.


APEX for RPT serves as a mark of distinction, signaling to patients and peers that a practice is equipped to deliver these therapies. APEX also fosters trust, helping patients feel confident in the care they receive, knowing it meets or exceeds national standards. Additionally, accredited practices are marked as leaders in the field, highlighting their ability to adapt to new technologies and deliver innovative treatments.

### Getting started

Getting started with the RPT-specific pathway, or the full APEX accreditation process, is easy. Practices can choose between pursuing RPT accreditation as a standalone offering or integrating it into their existing APEX accreditation. Both options provide practices specializing in RPT with the opportunity to be recognized for their expertise and dedication to quality care.

2024 is a big year for APEX, and ASTRO is proud to offer this new RPT pathway. Now is the perfect time to join over 450 facilities that have already committed to the APEX accreditation process.

Interested practices can contact [APExSupport@ASTRO.org](mailto:APExSupport@ASTRO.org) or schedule an individual interest meeting with ASTRO staff at <https://www.picktime.com/APExMeetings> to learn more about the process. Whether you're seeking the standalone RPT accreditation or the comprehensive APEX accreditation, ASTRO is here to help you every step of the way.

For more information, visit the ASTRO Resource Center in the East Salon AB where an APEX representative is available to meet with you. Take the next step in advancing your practice and demonstrating excellence in RPT! 

**The APEX session is scheduled for Monday, September 30, 8:00 a.m. - 9:00 a.m. in room 140.**

Join **EDU 17 – Elevating Excellence without the Extra Steps: APEX Insights and Innovative Strategies** live or watch onDemand.



# CONGRATULATIONS

## to the 2024 Annual Meeting Abstract Award Winners

ASTRO awards up to 45 investigators who submitted an abstract to the Annual Meeting with an achievement award. Winners are chosen based on their peer-reviewed scores and final abstract review by the Annual Meeting Steering Committee.

Congratulations to the 2024 Annual Meeting Abstract Award winners! To learn more about their research, search by name in the Annual Meeting Portal at [www.astro.org/AMportal](http://www.astro.org/AMportal).

### Leibel Award

The Steven A. Leibel Award was established in memory of Steven A. Leibel, MD, FASTRO, a former member of the American Board of Radiology (ABR) Board of Trustees and past president of the ABR as well as ASTRO. The ABR Foundation provides two award winners with \$2,000 each at the ASTRO Annual Meeting. Winners are selected by ASTRO leadership from the abstracts designated as Plenary or Clinical Trials presentations.



**Jay Detsky, MD, PhD**  
*Sunnybrook Health Sciences Centre*

MR-Linac On-Line Weekly Adaptive Radiotherapy for High Grade Glioma (HGG): Results from the UNITED Single Arm Phase II Trial



**Kenneth Merrell, MD, MS**  
*Mayo Clinic Alix School of Medicine*

A Prospective, Phase II Study of 177Lu-Dotatate in Patients with Surgery- and Radiation-Refractory Meningioma: Results of the WHO Grade II/III Cohort

### International Abstract Award

The international award is designed to foster continuing medical education, assist in career development and help establish relationships with ASTRO members who may serve as scientific mentors to the recipient. Only one award is given each year to candidates who receive the highest score among applicants. The award includes an honorarium, a certificate of recognition and a complimentary registration to the Annual Meeting.



**Smith Apisarnthanarax, MD**  
*University of Washington Radiation Oncology*

Survival Prediction with Albumin-Bilirubin (ALBI) Changes in Hepatocellular Carcinoma Patients Treated with External Beam Radiotherapy (EBRT)

### Resident Clinical/Basic Science Research Award

This award acknowledges clinical research being performed by young scientists. It is granted to the top resident author of a significant study in radiobiology, clinical research and physics. The award includes an honorarium, a certificate of recognition and a complimentary registration to the Annual Meeting.



**Christopher Jackson, MD, MS**  
*Memorial Sloan Kettering Cancer Center*

Risk of Radiation Myelitis after Hypofractionated Spine Stereotactic Body Radiation Therapy

### Resident Recognition Awards

The Resident Recognition awards acknowledge outstanding abstracts submitted by early career scientists, biologists and physicists that were accepted into one of two presentation types — Quick Pitch oral scientific session or Digital Poster Viewing. Winners receive a trophy to recognize their achievement.

#### RESIDENT RECOGNITION AWARD - QUICK PITCH



**Justin Barnes, MD, MS**  
*Washington University School of Medicine in St. Louis*

High Deductible Health Plans and Survival among Cancer Survivors and the Role of Cost-Driven Delayed or Forgone Medical Care



**Sifan Lu, BA**  
*SUNY Downstate College of Medicine*

Changes in Employment and Practice Locations among Radiation Oncologists: 2015 – 2023



**Anurag Saraf, MD**  
*Brigham and Women's Hospital/ Dana-Farber Cancer Institute*

TEAMRO: Final Analysis of TEAMRO (TEAching Mentorship in Radiation Oncology), A Multicenter Prospective Phase 2 Intervention Study on Teaching Mentorship Skills to Resident Physicians Working with Medical Students



**Colton Ladbury, MD**  
*City of Hope National Medical Center*

Radiation-Related Late Toxicities Following Total Marrow Irradiation Transplant Conditioning Regimens



**Anupam Rishi, MD**  
*H. Lee Moffitt Cancer Center*

Outcome and Pattern of Failure Following Definitive High-Dose Radiotherapy for Primary Vulvar CancEr: Interim Analysis of The DRIVE Multicenter Cohort Study



**Jessica Fleming, PhD**  
*The Ohio State University*

Clinical Endpoints Correlation with Molecular Features in the NRG Oncology/RTOG 9802 Low-Grade Glioma, Low-Risk Observation Arm



**Chelain Goodman, MD, PhD**  
*MD Anderson Cancer Center*

Circulating Tumor Cell Clearance Dynamics in Patients with Breast Cancer Undergoing Regional Nodal Radiotherapy: A Prospective Observational Cohort Study



**Samuel Zhang, MD**  
*Cedars-Sinai Medical Center*

The Effect of Palliative Radiotherapy Field Volume on Rates of Significant Hematologic Toxicity in Patients with Multiple Myeloma

#### RESIDENT RECOGNITION AWARD - POSTER VIEWING



**George Li, MD**  
*University of Toronto*

Treatment Toxicity and Outcomes Following Definitive Radiotherapy for Patients with Early-Stage Non-Small Cell Lung Cancers and Pre-Existing Interstitial Lung Disease – A Systematic Review



**Qifeng Wang, MD, PhD**  
*Sichuan Cancer Hospital and Institute*

Toripalimab plus Chemotherapy and Radiotherapy for Treatment-Naive, Advanced Esophageal Squamous Cell Carcinoma: A Single-Arm Phase II Trial



**Shalini Moningi, MD**  
*Brigham and Women's Hospital/ Dana Farber Cancer Institute*

Testosterone Recovery and Associated Impact on Patient-Reported Health-Related Quality of Life (HRQoL) after Treatment with 6 Months of GnRH Agonist with or without Abiraterone Acetate plus Prednisone (AAP) and Apalutamide (Apa) in the FORMULA-509 Trial



**Hannah Bacon, MD, PhD**  
*University of Toronto*

Dosimetric Predictors of Radiation Pneumonitis in Locally Advanced Non-Small Cell Lung Cancer Patients with Artificial-Intelligence Screened Interstitial Lung Disease



## Basic/Translational Science Award

This award is designed to encourage participation in the ASTRO Annual Meeting by basic and translational scientists. Up to 12 awards are given to applicants having the top-rated abstracts in clinical research, radiobiology and physics categories. Winners are a mixture of junior and senior level investigators. The award includes an honorarium, a certificate of recognition and a complimentary registration to the Annual Meeting.



**William Chen, MD**

*University of California San Francisco*

Luminal B Single-Cell Signature and Resistance to Hormone Therapy in Breast Cancer



**Adam Grippin, MD, PhD**

*MD Anderson Cancer Center*

IMMUNOCERV Phase II Trial Combining the HPV-Specific T Cell Immunotherapy PDS0101 with Chemoradiation for Treatment of Locally Advanced Cervical Cancer



**Matthew Gallitto, MD, PhD**

*Columbia University Irving Medical Center*

Convection-Enhanced Drug Delivery and Radiosensitization for Diffuse Midline Glioma



**Eric Stutheit-Zhao, MD, PhD**

*Princess Margaret Cancer Centre*


HPV-Seq is Prognostic in p16-Positive Oropharyngeal Cancer (OPC): Independent Validation on a Large Prospective Cohort and a Secondary Analysis of NRG-HN002



**Aadel Chaudhuri, MD, PhD**

*Mayo Clinic Alix School of Medicine*

Does Detection of Tumor-Associated Mutations in Proximal Lymph Predict Relapse in HPV-Negative Head and Neck Cancer Patients?



**Lin Ma, PhD**

*Mayo Clinic College of Medicine and Science Rochester*

DeepTuning: A Novel Deep Learning Approach for Interactive Plan Tuning and Trade-Off Exploration



**Benjamin Schrank, MD, PhD**

*MD Anderson Cancer Center*

A Microbial-Inspired Antibody-Drug Conjugate Unleashes Macrophage Functionalities for Cancer Immunotherapy



**Zi Yang, PhD**

*Stanford University*

A Deep Learning-Driven Framework for Large Language Model-Assisted Automatic Target Volume Localization and Delineation for Enhancing Spinal Metastases Stereotactic Body Radiotherapy Workflow



**Claire Lanier, MD**

*Wake Forest University School of Medicine*


Genomic Signature for Leptomeningeal Progression in Brain Metastasis Patients Using Liquid Biopsy-Acquired Comprehensive Genomic Profiling



**Ying Zhang, PhD**

*University of Texas Southwestern Medical Center at Dallas*


Deep Learning-Based Quick MLC Sequencing for MRI-Guided Online Adaptive Radiotherapy



**Christina Huang, MD, MS**

*Duke University Medical Center*

Long-Term Update of a Phase 2 Study of Dose-Reduced Consolidation Radiation Therapy in Diffuse Large B-Cell Lymphoma



**Beth Neilsen, MD, PhD**

*University of California Los Angeles*

Impact of Organ-at-Risk (OAR) Radiation Dosimetry on Acute and Late Toxicity after Prostate Stereotactic Body Radiation Therapy (SBRT): A Post-Hoc Analysis of a Phase III Randomized Clinical Trial of MRI-Guided vs. CT-Guided SBRT

## Annual Meeting Travel Awards

This award is designed to recognize outstanding abstracts submitted by early career scientists, biologists and physicists. Up to 15 awards are given (five in each category) to offset travel expenses to the meeting.



**Kevin Nead, MD, MPhil**

*MD Anderson Cancer Center*

Impact of Cancer Therapy on Clonal Hematopoiesis Mutations and Subsequent Clinical Outcomes



**Philip Sutera, MD**

*Johns Hopkins Radiation*

*Oncology Kimmel Cancer Center*

Genomic Predictors of Response to Metastasis Directed Therapy with or without Androgen Deprivation Therapy



**Vincent Bernard Pagan, MD, PhD**

*MD Anderson Cancer Center*

Characterizing Radiation Induced Subclonal Kinetics in Pancreatic Ductal Adenocarcinoma



**Alexander Goglia, MD, PhD**

*Memorial Sloan Kettering Cancer Center*

Prognostic Implications of Cerebrospinal Fluid Circulating Tumor DNA (CSF ctDNA) Following Radiation Therapy in Patients with Leptomeningeal Metastasis: Analysis of a Randomized Phase II Trial



**Danielle Bitterman, MD**

*Brigham and Women's Hospital/Dana-Farber Cancer Institute*

A Randomized Controlled Crossover Trial to Evaluate the Efficacy of AI-Assisted Heart Contouring



**Comron Hassanzadeh, MD, MPH**

*MD Anderson Cancer Center*

Hypofractionated, Dose-Escalated Radiation vs. Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase 3, Prospective, Randomized Controlled Trial



**Omran Saifi, MD**

*Mayo Clinic Florida*

Bridging Radiotherapy for Patients with Limited (<5 Disease Sites) Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma prior to CAR T-Cell Therapy



**Oi Wai Chau, PhD**

*Mayo Clinic Alix School of Medicine*

Assessing the Tumor Visibility and Respiratory Motion of Liver Cancer Patients on Multi-Task MR and 4D-CT Imaging for Radiation Treatment Planning



**Lydia Wilson, PhD**

*Thomas Jefferson University*

Results of a Prospective Trial to Evaluate Novel Lung Function Imaging for Lung Cancer Surgery



**Zeliang Ma, MD**

*Mayo Clinic Rochester*

Identifying Candidates for Postoperative Radiotherapy in Patients with Non-Small Lung Cancer: Multicenter Deep Learning Model Development and Prospective Validation


$$IQ + EQ = CQ$$

Our focus at CQ Medical is to make cancer and other treatments more precise, technology more effective and medical minds more brilliant.

Everything, from the way we do business to the way we develop and design product, is guided by our Care Quotient (CQ) Philosophy: That everything must have that unique and important mix of medical intellect and patient empathy.

In short, IQ + EQ = CQ.

That's how we care smarter than anyone. And care smarter for everyone.



**EXPLORE OUR NEW SOLUTIONS  
BOOTH #927**







# Best of ASTRO Officially Licensed Meetings

ASTRO offers licenses to host a Best of ASTRO meeting in your country!

**IN AN EFFORT TO SHARE** the most important scientific studies related to radiation oncology throughout the world, ASTRO has created a program that allows international organizations to license top-rated content from the 2024 Annual Meeting and hold an officially licensed Best of ASTRO meeting in countries around the globe.

The Best of ASTRO content represents over 100 of the top-rated abstracts included in the scientific program at the ASTRO Annual Meeting. These abstracts are hand-picked and feature cutting-edge research in all major disease sites, including the top-rated abstracts presented during the Plenary and Discussant-led Science Highlights sessions. The Best of ASTRO meeting allows attendees to hear these top abstracts presented in a practical and useful way from local leaders in the field of radiation oncology. Holding a Best of ASTRO meeting in your country offers you and your colleagues access to the top-rated abstracts presented in Washington, DC, and foster discussion and networking at a local level.

Information on application guidelines, fees, eligibility criteria, and the full licensing package can be found on the Meetings and Education page of the ASTRO website. A \$1,000 discount is available to those applying by the early-bird deadline of October 31, 2024, and special consideration may be offered for LMICs. Questions? Contact [meetings@astro.org](mailto:meetings@astro.org).

### International offerings

ASTRO is pleased to offer a variety of sessions for international meeting attendees or those with an interest in global oncology. As an attendee at the Annual Meeting, you'll benefit from formal and informal networking with colleagues from around the world.

The ASTRO International Committee has compiled a great selection of topics for international attendees. Sessions from the International Track include:

- International 01** - Implementing Innovations for Radiotherapy Delivery in Low- and Middle-Income Countries: Challenges and Opportunities; Sunday, September 29, 8:00 a.m.

- International 02** - Innovations in Radiation Oncology in Latin America; Sunday, September 29, 2:30 p.m.
- International 03** - Reirradiation in Clinical Practice: Navigating Current Evidence and Practical Solutions; Sunday, September 29, 4:45 p.m.
- International 04** - Lancet Oncology Commission on Theranostics and Radiotherapy: Toward Bridging the Gaps in Cancer Radiotherapy Access for All; Monday, September 30, 10:45 a.m.
- International 05** - New Applications of Radiation Therapy: Starting a Program in a Low-Resource Setting; Monday, September 30, 3:00 p.m.
- International 06** - Building Radiation Capacity in Africa through Collaborations in Research and Training – Voices from ASTRO and AORTIC Members; Monday, September 30, 5:00 p.m.
- International 07** - Rethinking Clinical Trials: A Global Perspective from Academia, Cooperative Groups and Industry; Tuesday, October 1, 2:30 p.m.

### Other international activities include:

- The **International Breakfast** on Monday, September 30, at 7:00 a.m. in Room 146. All international attendees are invited to meet one another and network while enjoying breakfast and hearing updates from the ASTRO International Committee. Hosted by ASTRO (for international attendees only).
- A **joint session with the European Society of Radiation Oncology (ESTRO) on Radiopharmaceuticals**, EDU 62, will be presented on Tuesday, October 1 at 5:15 p.m.



Be sure to pick up an international attendee Journey Map from the registration area or the ASTRO Resource Center. These handy guides list sessions specifically curated for international attendees.

# ASTRO SOCIAL CHAMPIONS

#ASTRO24



**Armando Félix, MD**  
@ArmandoFelix70



**Dasha Klebaner, MD, MPH**  
@DashaKlebaner



**Jenna Kocsis, MD**  
@jkocsis11



**Colton Ladbury, MD**  
@ColtonLadbury



**Shearwood McClelland III, MD**  
@TheDrWood




**Haidy G. Nasief, PhD**  
@DrHaidyNasief



**Tamer Refaat, MD, PhD, MSCI**  
@TamerRefaatMD



**Parisa Shamsesfandabadi, MD**  
@P\_Shams\_



**Yasamin Sharifzadeh, MD**  
@yazshaz



**Rehema J. Thomas, MD**  
@RadiantRehema


## 2024 ANNUAL MEETING PROMOTIONAL SPONSORS


## Expanding access for Hispanic breast cancer patients

Meet the team presenting preliminary research for new Radiation Oncology Institute award



Shearwood  
McClelland III, MD




Abizairie  
Sánchez-Feliciano, BS

**SHEARWOOD MCCLELLAND III, MD**, is the recipient of one of the Radiation Oncology Institute's (ROI) 2024 Advancing Care for All: Innovations to Drive Access to Radiotherapy Awards, which will help expand his research to reduce disparities in radiation therapy access facing underrepresented minorities in the United States. The focus of his research is on utilizing hypofractionation and navigators to support patients by helping to ensure they complete their treatment as planned and limit the financial toxicity of their care. Dr. McClelland and his colleagues initially launched the Navigator-Assisted Hypofractionation (NAVAH) program at the University Hospitals Cleveland Medical Center to improve outcomes for African American breast cancer patients. They will build upon the success of this work to adapt the program for Hispanic American breast cancer patients with the new grant from ROI. Dr. McClelland's team is partnering with members of their local Hispanic/Latinx community to tailor the navigation experience based on language and culture and then will conduct the first randomized controlled trial on the impact of patient navigation on radiation therapy treatment completion and financial toxicity in Hispanic American breast cancer patients.

Last year, Dr. McClelland began to lay the foundation for expanding the NAVAH program to Hispanic American patients with lab member Abizairie Sánchez-Feliciano, BS, a student in the Case Western


Reserve University School of Medicine class of 2026. Ms. Sánchez-Feliciano was recognized for this work with a 2023 ASTRO Medical Student Fellowship Award and is presenting her results at this year's Annual Meeting. **During Poster Q&A 01: Lung Cancer/Thoracic Malignancies and Diversity, Equity and Inclusion in Healthcare, Ms. Sánchez-Feliciano will present abstract 2132 "Validation of Spanish-Language Surveys Utilized for the Navigator-Assisted Hypofractionation Program to Aid Hispanic-American Breast Cancer Patients."**

"I am extremely proud of Abizairie and her work on the Spanish-language surveys that she is presenting at the Annual Meeting," says Dr. McClelland. "We are excited to expand our Navigator-Assisted Hypofractionation program to Hispanic American breast cancer patients with support from ROI to help more people get the care they need and to continue to reduce disparities in care in our community."

Learn more about this transformative research from Ms. Sánchez-Feliciano and Dr. McClelland today from 2:45 p.m. to 4:15 p.m. in Hall C. The survey is a critical component of the NAVAH program for Hispanic American breast cancer patients, and ROI is looking forward to seeing the results of their new clinical trial presented at a future ASTRO Annual Meeting. For more information about ROI, visit [ROIInstitute.org](https://ROIInstitute.org). 

# What could an ultrasensitive cell-free HPV DNA assay offer to your patient?

**97.6%**  
Clinical sensitivity



Learn more about our assay at Booth 906.



At Sysmex Inostics, we recognize the critical role of cfHPV-DNA monitoring in optimizing patient care and treatment management for head and neck and other HPV-driven cancers. We are committed to bring this novel biomarker to every patient suffering from HPV-driven cancers.



Sysmex Inostics, Inc. 1812 Ashland Ave, Suite 500, Baltimore, MD 21205, USA [info@sysmex-inostics.com](mailto:info@sysmex-inostics.com) [www.sysmex-inostics.com](http://www.sysmex-inostics.com)

© 2024 Sysmex Inostics, Inc. HPV-SEQ panel is a Laboratory Developed Test (LDT) supplied by Sysmex Inostics, Inc. at their CLIA-certified laboratory in Baltimore, Maryland, and has not been cleared or approved by the US Food and Drug Administration. HPV-SEQ panel is not intended for first-line oncology screening or diagnosis and should be used in conjunction with other patient information to help inform clinical decision-making.

ASTROAD0.SPG.9/20





Visit the Product Showcase located in the Hall B Rotunda between Halls A and B Exhibit Hall entrances to learn about the products featured in the Product Showcase. Scan the QR code to view products on the Annual Meeting Portal, including photos, videos and detailed information about each product.



## ACCURAY

**Booth Number:** 1027

**Product Name:** The CyberKnife® System



## ACCURAY

**Booth Number:** 1027

**Product Name:** The Radixact® System



## C/STLE BIOSCIENCES

**Booth Number:** 2612

**Product Name:** DecisionDx-SCC



## C-RAD

**Booth Number:** 1403

**Product Name:** Catalyst+ HD



## Klarity

**Booth Number:** 2517

**Product Name:** Klarity Athena™ Supine Breast System



## LANTHEUS

**Booth Number:** 613

**Product Name:** PYLARIFY



## mim SOFTWARE

**Booth Number:** 1511

**Product Name:** MIM Maestro®



## NELCO WORLDWIDE

**Booth Number:** 627

**Product Name:** Room Renovation and Equipment Upgrades



## novocure


**Booth Number:** 1327

**Product Name:** Optune Gio



**Booth Number:** 909

**Product Name:** DCISionRT



## RAD formation

**Booth Number:** 2627

**Product Name:** AutoContour: Powerful AI-Driven Automation



## Sensus+

**Booth Number:** 837

**Product Name:** SRT-100 Vision, SRT Series



## SERVIER moved by you

**Booth Number:** 1043

**Product Name:** VORANIGO (vorasidenib) Tablets



## varian A Siemens Healthineers Company

**Booth Number:** 1627

**Product Name:** Eclipse Treatment Planning System



## varian A Siemens Healthineers Company

**Booth Number:** 1627

**Product Name:** HyperSight Imaging Solution

## INDUSTRY-EXPERT THEATERS

📍 Theaters 1 and 2 are located in Hall C of the Exhibit Hall.  
Room 154 AB is located on the Street Level of the Walter E. Washington Convention Center.

### SUNDAY, SEPTEMBER 29

#### 📍 Theater 1

**12:00 p.m. - 1:00 p.m. | Blue Earth Diagnostics, Inc.**

*Let's Talk About POSLUMA® (flotufolastat F18)*

#### 📍 Theater 2

**12:00 p.m. - 1:00 p.m. | AstraZeneca**

*The Role of Radiation Oncology in Managing Patients with Unresectable Stage III Non-Small Cell Lung Cancer*

#### 📍 Room 154

**12:00 p.m. - 1:00 p.m. | GE HealthCare**

*Data-Enhanced Strategies in Improving Radiation Therapy Outcomes*

#### 📍 Theater 1

**2:00 p.m. - 3:00 p.m. | Sumitomo Heavy Industries, Ltd.**

*Clinical Experience with Accelerator Based BNCT System in Japan*

#### 📍 Theater 2

**2:00 p.m. - 3:00 p.m. | Accuray**

*Evolving Techniques in CNS Radiosurgery: Historical, Contemporary, and Future Directions*

#### 📍 Room 154

**2:00 p.m. - 3:00 p.m. | BioProtect**

*Safely Dissecting the Data and Real-World Experience of Rectal Spacers: Redefining Precision and Safety with the BioProtect Balloon Implant*

## UNRESTRICTED EDUCATIONAL GRANT SUPPORTERS

**Lantheus**

**Merck & Co., Inc.**

**Novartis Pharmaceuticals Corporation**

**Pfizer, Inc.**

## INDUSTRY SATELLITE SYMPOSIA

### SUNDAY, SEPTEMBER 29

6:00 p.m. - 6:30 p.m. | Registration & Dinner  
6:30 p.m. - 8:30 p.m. | Symposium (will be livestreamed)

*New Frontiers in Immunotherapy for SCLC: Insights from the Latest Clinical Trials and Their Application in Real-World Treatment*

Location: Marriott Marquis Washington, DC  
Marquis Ballroom 3-4  
901 Massachusetts Avenue, NW  
Washington, DC

For more information or to register, please visit [gotoper.com/radonc](https://gotoper.com/radonc).

**CME Credits:** Physicians' Education Resource®, LLC, designates this live activity for a maximum of 2 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

*This activity is supported by an educational grant from AstraZeneca, Inc.*



## DEI LOUNGE

📍 Room 156, Street Level

Sunday, September 29 – Tuesday, October 1

10:00 a.m. - 5:00 p.m.

This is a networking space for all where diverse experiences and perspectives are valued. Meeting attendees wishing to connect, take a break or hold informal group meetups in a supportive environment are welcome.



## EARLY CAREER AND MENTORING LOUNGE

Saturday – Tuesday | 📍 East Salon C

We are excited to offer a dedicated space for Early Career members to relax, connect with peers and meet for one-on-one mentoring. New this year, we're also introducing programming to include an Early Career Committee Meeting open to all Early Career attendees and a Committee Fair to learn about ASTRO committee work and more.

Visit [www.astro.org/AMECLounge](https://www.astro.org/AMECLounge) for the full schedule.





Connect with us at ASTRO 2024  
Booth #2145

# Defying Convention. Empowering Radiation Oncologists.

Come learn about the novel radiopharmaceutical  
Phospholipid Drug Conjugate (PDC)<sup>™</sup> platform  
in hematology and solid tumors.

Cellectar Biosciences is a late-stage, clinical  
biopharmaceutical company developing a  
proprietary PDC platform with the ability to  
deliver a broad array of therapeutic modalities  
to target cancers.

Want more details? Get in touch with us.





# Best™ *medical international*

A TEAMBEST GLOBAL COMPANY

TEAMBEST GLOBAL®



www.teambest.com



## Best GammaBeam™ 100/300 Equinox™ Teletherapy System with Avanza™ 6D Patient Positioning Table

With **NEW** Multi-Leaf Collimator for 80 and 100 cm SAD units—IMRT, IGRT, SRS, SBRT and Tomotherapy capable with ActiveRx



Best™ Gammacell® 1000/3000 Blood & Research Irradiator

## UPGRADE KIT for all old Theratron units, 80 or 100 cm including IMRT capabilities w/built in or external MLC



### UPGRADE includes:

- Removing all old controls, electronics and installing a new control system and covers
- Replacing the old collimator system with the new Equinox collimator
- Replacing the old treatment table with the new Avanza™ Table
- Retaining the head rotation capability is optional

### UPGRADE features:

- Calculated Arc Speed
- Graphical Control System
- Asymmetric Jaws (optional)
- R&V System Ready (optional)
- Service Log Files
- On-Board Verification
- Motorized Wedge (optional)
- Collision Detection (optional)



Best™ Raycell Mk2 Blood & Research Irradiator



Best™ Raycell Mk1 Blood & Research Irradiator

Best Theratronics Ltd., 413 March Road, Ottawa, Ontario K2K 0E4 Canada  
tel: 613 591 2100 866 792 8598 www.theratronics.com www.teambest.com

\*Certain products shown are not available for sale currently. TeamBest Global Companies ©2024